Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushing's Disease
Acromegaly
Neuroendocrine Tumors
Pituitary Tumors
Ectopic ACTH Secreting (EAS) Tumors
Dumping Syndrome
Prostate Cancer
Melanoma Negative for bRAF
Melanoma Negative for nRAS

Interventions

DRUG: Pasireotide
DRUG: Cabergoline
DRUG: Pasireotide LAR

Sponsor

RECORDATI GROUP